TD Asset Management Inc Cuts Position in IQVIA Holdings Inc. $IQV

TD Asset Management Inc decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 15.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 99,507 shares of the medical research company’s stock after selling 17,770 shares during the quarter. TD Asset Management Inc owned 0.06% of IQVIA worth $22,430,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IQV. Boston Partners purchased a new position in shares of IQVIA during the 3rd quarter valued at approximately $676,698,000. Norges Bank acquired a new position in IQVIA during the fourth quarter worth $497,445,000. AQR Capital Management LLC lifted its holdings in IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares in the last quarter. Citigroup Inc. grew its position in shares of IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after purchasing an additional 475,557 shares during the period. Finally, Invesco Ltd. increased its stake in shares of IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after purchasing an additional 367,204 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Up 0.1%

NYSE IQV opened at $183.56 on Monday. The business’s fifty day simple moving average is $172.12 and its 200-day simple moving average is $194.79. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $30.64 billion, a PE ratio of 22.75, a P/E/G ratio of 1.57 and a beta of 1.21. IQVIA Holdings Inc. has a 52 week low of $147.62 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Mizuho set a $215.00 price target on shares of IQVIA in a research note on Monday, February 23rd. Evercore reiterated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. HSBC set a $210.00 target price on IQVIA in a report on Wednesday. Truist Financial lowered their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Finally, Royal Bank Of Canada assumed coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, IQVIA has a consensus rating of “Buy” and a consensus target price of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.